Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop.

BACKGROUND In vivo gene transfer into injured arteries may provide a new means to facilitate molecular understanding of and to treat the intractable fibroproliferative arterial diseases. Selection of an optimal molecule to be transferred will be a key to successful gene therapy in the future. We tested the hypothesis that a secreted multifactorial molecule should act more efficiently through an autocrine/paracrine loop to suppress neointimal formation elicited in injured arteries than a simple growth-inhibiting molecule that might be expressed inside cells. METHODS AND RESULTS We constructed an adenoviral vector (AdCACNP) expressing C-type natriuretic peptide (CNP), a secreted stimulator of membrane-bound guanyl cyclase. AdCACNP directs cells to secrete large quantities of biologically active CNP. Serum-stimulated DNA synthesis and cell proliferation were only moderately suppressed in arterial smooth muscle cells infected with AdCACNP in vitro. However, when AdCACNP was applied to balloon-injured rat carotid arteries in vivo, neointimal formation was markedly reduced (90% reduction) in an infection-site-specific manner without an increase in plasma CNP level. CONCLUSIONS Our results showed that CNP, a secreted multifactorial molecule, was indeed effective in suppressing fibroproliferative response in injured arteries and suggest that the potent antiproliferation effect may not be the most critical factor for the effective suppression of neointimal formation. An adenovirus-mediated expression of CNP could be an effective and site-specific form of molecular intervention in proliferative arterial diseases.

[1]  A. Takeshita,et al.  Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[2]  A. Takeshita,et al.  Adenovirus‐Mediated Transfer of Cyclin‐dependent Kinase Inhibitor‐p21 Suppresses Neointimal Formation in the Balloon‐Injured Rat Carotid Arteries in Vivo a , 1997, Annals of the New York Academy of Sciences.

[3]  T. Igaki,et al.  Regulation of secretion and clearance of C-type natriuretic peptide in the interaction of vascular endothelial cells and smooth muscle cells. , 1996, Journal of hypertension.

[4]  R. Virmani,et al.  Local adenoviral–mediated expression of recombinant hirudin reduces neointima formation after arterial injury , 1996, Nature Medicine.

[5]  Y. Kanegae,et al.  Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Leiden,et al.  Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. , 1995, The Journal of clinical investigation.

[7]  T. Wight,et al.  The extracellular matrix and atherosclerosis , 1995, Current opinion in lipidology.

[8]  M. Kohno,et al.  Inhibition by cardiac natriuretic peptides of rat vascular endothelial cell migration. , 1995, Hypertension.

[9]  S M Schwartz,et al.  The intima. Soil for atherosclerosis and restenosis. , 1995, Circulation research.

[10]  A. Takeshita,et al.  Percutaneous transluminal gene transfer into canine myocardium in vivo by replication-defective adenovirus. , 1995, Cardiovascular research.

[11]  G. Condorelli,et al.  Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo , 1995, Nature Medicine.

[12]  T. Saruta,et al.  Natriuretic peptide-augmented induction of nitric oxide synthase through cyclic guanosine 3',5'-monophosphate elevation in vascular smooth muscle cells. , 1995, Endocrinology.

[13]  D. Atsma,et al.  cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. , 1995, Circulation research.

[14]  J. Seltzer,et al.  Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product , 1995, Science.

[15]  M. Shinomiya,et al.  C-type natriuretic peptide inhibits intimal thickening of rabbit carotid artery after balloon catheter injury. , 1994, Biochemical and biophysical research communications.

[16]  E. Nabel,et al.  Gene therapy for vascular smooth muscle cell proliferation after arterial injury. , 1994, Science.

[17]  G. R. Dodge,et al.  Transcatheter Delivery of c‐myc Antisense Oligomers Reduces Neointimal Formation in a Porcine Model of Coronary Artery Balloon Injury , 1994, Circulation.

[18]  L. Hillis,et al.  Percutaneous transluminal coronary angioplasty. , 1994, The American journal of the medical sciences.

[19]  D. Garbers,et al.  The family of guanylyl cyclase receptors and their ligands. , 1994, Endocrine reviews.

[20]  N. Minamino,et al.  C-type natriuretic peptide inhibits intimal thickening after vascular injury. , 1993, Biochemical and biophysical research communications.

[21]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[22]  A. Kenny,et al.  Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. , 1993, The Biochemical journal.

[23]  K. Miyamoto,et al.  Stable expression of natriuretic peptide receptors: effects of HS-142-1, a non-peptide ANP antagonist. , 1992, Biochemical and biophysical research communications.

[24]  J. Lewicki,et al.  C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells. , 1992, The American journal of physiology.

[25]  Y. Komatsu,et al.  Vascular natriuretic peptide , 1992, The Lancet.

[26]  Michael Simons,et al.  Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo , 1992, Nature.

[27]  K. Hosoda,et al.  Phenotype-related alteration in expression of natriuretic peptide receptors in aortic smooth muscle cells. , 1992, Circulation research.

[28]  N. Minamino,et al.  Structural requirements of C-type natriuretic peptide for elevation of cyclic GMP in cultured vascular smooth muscle cells. , 1992, Biochemical and biophysical research communications.

[29]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[30]  N. Minamino,et al.  C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. , 1991, Biochemical and biophysical research communications.

[31]  J. Folts.  An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. , 1991, Circulation.

[32]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[33]  D. Goeddel,et al.  Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). , 1991, Science.

[34]  M. Fishbein,et al.  A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. , 1991, Journal of the American College of Cardiology.

[35]  N. Minamino,et al.  Cloning and sequence analysis of a cDNA encoding a precursor for rat C‐type natriuretic peptide (CNP) , 1990, FEBS letters.

[36]  N. Minamino,et al.  N-terminally extended form of C-type natriuretic peptide (CNP-53) identified in porcine brain. , 1990, Biochemical and biophysical research communications.

[37]  J. Lewicki,et al.  Physiological role of silent receptors of atrial natriuretic factor. , 1987, Science.